Fosamax 70mg extended indications for man's osteoporosis

Published: 2004-11-26 06:57:00

Updated: 2004-11-26 06:57:00

MSD Korea has extended the indication of Fosamax 70mg under the KFDA approval from the current osteoporosis treatment for the post menopause women by administering once a week, to osteoporosis for the men in the future, which will be NHI reimbursable at a similar standard with other osteoporosis ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK